• 1
    Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006; 7: 505-516.
  • 2
    Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis [abstract]. Eur J Cancer. 2001; 37( suppl 4): S9-15 Abstract.
  • 3
    Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366: 2-16.
  • 4
    Di Fiore PP, Pierce JH, Fleming TP, et al. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell. 1987; 51: 1063-1070.
  • 5
    Massarweh S, Osborne CK, Jiang S, et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006; 66: 8266-8273.
  • 6
    Ferrero JM, Ramaioli A, Largillier R, et al. Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol. 2001; 12: 841-846.
  • 7
    Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat. 1994; 29: 41-49.
  • 8
    Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB, Rose C. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol. 2001; 19: 3376-3384.
  • 9
    Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 1992; 13: 3-17.
  • 10
    Newby JC, Johnston SR, Smith IE, Dowsett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res. 1997; 3: 1643-1651.
  • 11
    Nicholson RI, McClelland RA, Gee JM, et al. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat. 1994; 29: 117-125.
  • 12
    Pawlowski V, Révillion F, Hebbar M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res. 2000; 6: 4217-4225.
  • 13
    Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat. 2002; 71: 67-75.
  • 14
    Rampaul RS, Pinder SE, Nicholson RI, Gullick WJ, Robertson JF, Ellis IO. Clinical value of epidermal growth factor receptor expression in primary breast cancer. Adv Anat Pathol. 2005; 12: 271-273.
  • 15
    Skasko E, Paszko Z, Mazur S. A new look at the prognostic value of the estrogen, progesterone and epidermal growth factor receptors in breast cancer tissue. Neoplasma. 2005; 52: 10-17.
  • 16
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193: 265-275.
  • 17
    Ciocca DR, Fujimura FK, Tandon AK, et al. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst. 1992; 84: 1279-1282.
  • 18
    Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire, WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989; 7: 1120-1128.
  • 19
    McGuire WL, De La Garza M, Chamness GC. Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res. 1977; 37: 637-639.
  • 20
    Powell B, Garola RE, Chamness GC, McGuire WL. Measurement of progesterone receptor in human breast cancer biopsies. Cancer Res. 1979; 39: 1678-1682.
  • 21
    Ravdin PM, Green S, Dorr TM. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992; 10: 1284-1291.
  • 22
    Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in 2 large breast cancer databases. J Clin Oncol. 2003; 21: 1973-1979.
  • 23
    Clark GM, Osborne, CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor and patient characteristics in human breast cancer. J Clin Oncol. 1984; 2: 1102-1109.
  • 24
    Wenger CR, Clark GM. S-phase fraction and breast cancer—a decade of experience. Breast Cancer Res Treat. 1998; 51: 255-265.
  • 25
    Huang H, Neven P, Drijkoningen M. Association between tumor characteristics and HER-2/neu by immuniohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol. 2005; 58: 611-616.
  • 26
    Balleine RL, Earl MJ, Greenberg ML, Clarke CL. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer. 1999; 79: 1564-1571.
  • 27
    Dowsett M, Bundred NJ, Decensi A. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double- blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev. 2001; 10: 961-966.
  • 28
    Bamberger AM, et al. Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm Res. 2000; 54: 32-37.
  • 29
    Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. Clin Cancer Res. 2004; 10: 5670-5676.
  • 30
    Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005; 97: 1254-1261.
  • 31
    Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003; 95: 142-153.
  • 32
    Dowsett M, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according to oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 2006; 17: 818-826.
  • 33
    Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer. 2006; 13( suppl 1): S15-24.
  • 34
    Massarweh S, Osborne CK, Creighton CJ. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008; 68: 826-833.
  • 35
    She QB, Solit DB, Ye, Q, O'Reilly KE., Lobo J, Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell. 2005; 8: 287-297.
  • 36
    Bokemeyer C, Bondarenko I, Hartmann JT., et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 4000.
  • 37
    Darwish, S., Ludovini, V., Pistola, L., et al. EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients [abstract]. J Clin Oncol. 2008; 26( suppl). Abstract 22003.
  • 38
    Van Cutsem, E., Lang, I., D'haens, G., et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [abstract]. J Clin Oncol. 2008. 26( suppl). Abstract 2.
  • 39
    Chan SK, Hill ME, Gullick WJ. The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia. 2006; 11: 3-11.
  • 40
    Emlet DR, Schwartz R, Brown KA, Pollice AA, Smith CA, Shackney SE. HER2 expression as a potential marker for response to therapy targeted to the EGFR. Br J Cancer. 2006; 94: 1144-1153.
  • 41
    Giltnane JM, Rydén L, Cregger M, Bendahl PO, Jirström K, Rimm DL. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol. 2007; 25: 3007-3014.
  • 42
    Sorlie T, Perou CM, Tibshirani R. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 10869-10874.
  • 43
    Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.
  • 44
    Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006; 19: 264-271.
  • 45
    Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 5367-5374.
  • 46
    van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415: 530-536.
  • 47
    Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004; 96: 926-935.
  • 48
    Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2: 127-137.
  • 49
    Albain, K., Elledge, R.M., Gradishar, W.J., et al. Open-label, phase II, multicenter trial of ZD1839 (“Iressa”) in patients with advanced breast cancer. Breast Cancer Res Treat. 2002; 76( 1 suppl). Abstract 20.
  • 50
    Osborne, C.K., Neven, P., Dirix, L., et al. Randomized phase II study of gefitinib (Iressa) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat. 2007; 106( S1): 1-350.
  • 51
    Polychronis A, Sinnett HD, Hadjiminas D, et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol. 2005; 6: 383-391.
  • 52
    Carey LA, Rugo HS, Marcom PK, et al on behalf of the Translational Breast Cancer Research Consortium. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol. 2008; 26( suppl). Abstract 1009.
  • 53
    Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 2003; 22: 2812-2822.
  • 54
    Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-1500.
  • 55
    Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.